Lava Therapeutics Nv Quick Ratio (LVTX) starting from the third quarter 2025 to third quarter 2023, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Lava Therapeutics Nv  (NASDAQ: LVTX)

Lava Therapeutics Nv's Quick Ratio

LVTX's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Lava Therapeutics Nv's Cash & cash equivalent grew by 20.32 % in the Q3 2025 sequentially, while Current Liabilities decreased, this led to improvement in Lava Therapeutics Nv's Quick Ratio to 23.48 a new company high.

Within Major Pharmaceutical Preparations industry 25 other companies have achieved higher Quick Ratio than Lava Therapeutics Nv in third quarter 2025. While Quick Ratio total ranking in the third quarter 2025 has deteriorated compared to the prior quarter from 58 to 159.

Explain Quick Ratio?
How much Cash & cash equivalents LVTX´s has?
What are LVTX´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

LVTX Quick Ratio (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2		 (Mar 31 2025)
Q1		 (Dec 31 2024)
Q4		 (Dec 31 2023)
Q3
Y / Y Current Liabilities Change -70.78 % -31.3 % 184.74 % 526.36 % -
Y / Y Cash & cash equivalent Change -28.89 % -17.69 % 16.95 % 605.62 % -
Quick Ratio MRQ 23.48 13.97 5.46 3.93 9.65
LVTX's Total Ranking # 159 # 58 # 375 # 0 #
Seq. Current Liabilities Change -28.43 % -69.63 % -31.51 % 96.31 % 68.26 %
Seq. Cash & cash equivalent Change 20.32 % -22.3 % -4.79 % -20.12 % 39.27 %



Quick Ratio third quarter 2025 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 26
Healthcare Sector # 38
Overall Market # 159


Quick Ratio Statistics
High Average Low
23.48 10.62 3.49
(Sep 30 2025)   (Dec 31 2020)




Financial Statements
Lava Therapeutics Nv's Current Liabilities $ 4 Millions Visit LVTX's Balance sheet
Lava Therapeutics Nv's Cash & cash equivalent $ 99 Millions Visit LVTX's Balance sheet
Source of LVTX's Sales Visit LVTX's Sales by Geography


Cumulative Lava Therapeutics Nv's Quick Ratio

LVTX's Quick Ratio for the trailling 12 Months

LVTX Quick Ratio

 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months		 (Mar 31 2025)
12 Months		 (Dec 31 2024)
12 Months		 (Dec 31 2023)
12 Months
Y / Y Current Liabilities TTM Growth 68.42 % 241.76 % 523.96 % 1185.7 % -
Y / Y Cash & cash equivalent TTM Growth 15.31 % 112.64 % 329.25 % 2697.75 % -
Quick Ratio TTM 6.89 6.45 6.45 7.59 10.06
Total Ranking TTM # 3649 # 0 # 0 # 0 #
Seq. Current Liabilities TTM Growth -15.01 % -3.79 % 21.65 % 69.32 % 72.47 %
Seq. Cash & cash equivalent TTM Growth -9.17 % -3.88 % 3.48 % 27.63 % 67.5 %

Quick ratio ranking by company, industry and sector >> Back to LVTX Financial Strength Comparisons >> Go to Compare LVTX Quick Ratio to its Competitors

On the trailing twelve months basis Current Liabilities decreased faster than Lava Therapeutics Nv's average Cash & cash equivalent, this led to increase in in Lava Therapeutics Nv's Quick Ratio to 6.89, above LVTX average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 474 other companies have achieved higher Quick Ratio than Lava Therapeutics Nv. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2025 from 0 to 3649.

Explain Quick Ratio?
How much Cash & cash equivalents LVTX´s has?
What are LVTX´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 475
Healthcare Sector # 946
Within the Market # 3649


trailing twelve months Quick Ratio Statistics
High Average Low
6.51 6.51 6.51
(Sep 30 2025)  




Companies with similar Quick Ratio in the quarter ending Sep 30 2025, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2025 MRQ Cash & cash equivalentSep 30 2025 MRQ Current Liabilities
Lb Pharmaceuticals Inc  53.15 $ 314.479  Millions$ 5.917  Millions
Benitec Biopharma Inc   50.23 $ 94.534  Millions$ 1.882  Millions
Monopar Therapeutics Inc   49.71 $ 127.677  Millions$ 2.569  Millions
Curanex Pharmaceuticals Inc  46.70 $ 5.831  Millions$ 0.125  Millions
Altimmune inc   43.88 $ 210.776  Millions$ 4.804  Millions
Xbiotech Inc   41.34 $ 147.367  Millions$ 3.565  Millions
Belite Bio Inc  36.61 $ 352.932  Millions$ 9.641  Millions
Rapport Therapeutics Inc   35.84 $ 513.026  Millions$ 14.316  Millions
Bright Minds Biosciences Inc   35.59 $ 63.669  Millions$ 1.789  Millions
Janux Therapeutics Inc   35.54 $ 988.993  Millions$ 27.831  Millions
Inhibitor Therapeutics Inc   34.01 $ 2.977  Millions$ 0.088  Millions
Disc Medicine Inc   33.50 $ 615.920  Millions$ 18.383  Millions
Roivant Sciences Ltd   32.77 $ 4,385.835  Millions$ 133.857  Millions
Mbx Biosciences Inc   32.47 $ 391.673  Millions$ 12.062  Millions
Upstream Bio Inc   31.28 $ 372.427  Millions$ 11.908  Millions
Repare Therapeutics Inc   30.54 $ 112.604  Millions$ 3.687  Millions
Keros Therapeutics Inc   28.78 $ 693.472  Millions$ 24.092  Millions
Contineum Therapeutics Inc   28.68 $ 182.407  Millions$ 6.361  Millions
Viking Therapeutics Inc   27.88 $ 714.570  Millions$ 25.630  Millions
Liquidia Corporation  26.17 $ 157.496  Millions$ 6.019  Millions
Edgewise Therapeutics inc   26.03 $ 563.340  Millions$ 21.646  Millions
Prothena Corporation Public Limited Company  25.09 $ 330.843  Millions$ 13.188  Millions
Immuneering Corporation  24.83 $ 227.563  Millions$ 9.164  Millions
Psyence Biomedical ltd   23.53 $ 7.150  Millions$ 0.304  Millions
Lava Therapeutics Nv  23.48 $ 99.364  Millions$ 4.231  Millions
Trevi Therapeutics Inc   22.29 $ 194.927  Millions$ 8.745  Millions
Ligand Pharmaceuticals Incorporated  21.76 $ 664.522  Millions$ 30.539  Millions
Aprea Therapeutics Inc   21.39 $ 13.718  Millions$ 0.641  Millions
Stoke Therapeutics Inc   21.34 $ 248.310  Millions$ 11.634  Millions
Cervomed Inc   20.23 $ 27.294  Millions$ 1.349  Millions

Date modified: 2026-09-26T07:43:05+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.